#1 Clinical Trials Search in Europe

POLYMYXIN B SULFATE

Polymyxin B sulfate has emerged as a critical antibiotic in the treatment of multidrug-resistant gram-negative bacterial infections. As antibiotic resistance continues to rise globally, researchers are investigating various administration methods, dosing strategies, and combination therapies involving Polymyxin B to maximize effectiveness while minimizing toxicity. Clinical trials are examining its use in treating ventilator-associated pneumonia, bloodstream infections, intracranial infections, and hospital-acquired pneumonia caused by extensively drug-resistant (XDR) bacteria. These studies aim to determine optimal treatment protocols, evaluate the efficacy of combination therapies versus monotherapy, and assess pharmacokinetic properties across different patient populations. This article explores the current landscape of clinical research on Polymyxin B sulfate in combating serious bacterial infections.

Table of Contents

What is Polymyxin B Sulfate?

Polymyxin B sulfate is an antibiotic medication used to treat serious infections caused by certain types of bacteria. It belongs to the class of medications known as polymyxins, which are considered “last-resort” antibiotics used when other antibiotics have failed to work against resistant bacteria [1]. The drug is particularly effective against what are called “Gram-negative bacteria,” a classification based on how bacteria react to a specific staining procedure used in laboratories.

Polymyxin B is sometimes referred to by other names or brand names in different countries and may be included in combination products with other antibiotics. It has been in clinical use for several decades but has gained renewed importance in recent years due to the rise of antibiotic resistance worldwide [2].

How Polymyxin B Works

Polymyxin B works through several mechanisms to fight bacterial infections. Understanding how it works helps explain both its effectiveness and some of its side effects:

  • It disrupts the bacterial cell membrane by binding to and displacing calcium and magnesium molecules in the outer membrane of Gram-negative bacteria. This causes the bacterial membrane to become more permeable, leading to leakage of cell contents, cell lysis (rupture), and eventually bacterial death [5].
  • It acts as a surfactant (a substance that reduces surface tension). Being amphipathic (containing both water-loving and water-repelling parts), it can penetrate bacterial cell membranes and interact with the phospholipids inside, quickly disrupting the membrane structure [5].
  • It can bind to and neutralize bacterial endotoxins, which are toxic components released from the cell walls of Gram-negative bacteria. This helps reduce the inflammatory response in the body caused by these toxins [5].

This targeted mechanism means polymyxin B is only effective against Gram-negative bacteria and not against other types of microorganisms like Gram-positive bacteria, fungi, or viruses [5].

Medical Uses

Polymyxin B sulfate is used to treat a variety of serious infections caused by Gram-negative bacteria. Based on clinical research, it is particularly effective for:

  • Hospital-acquired infections – Infections that develop during hospital stays, especially in intensive care units [1].
  • Ventilator-associated pneumonia (VAP) – Lung infections that develop in patients who are on mechanical ventilation [9].
  • Hospital-acquired pneumonia (HAP) – Lung infections acquired in hospital settings [19].
  • Bloodstream infections (bacteremia) – Serious infections where bacteria enter the bloodstream [4].
  • Intracranial infections – Infections affecting the brain or surrounding tissues [2].
  • Complicated urinary tract infections – Serious infections of the urinary system [3].

Polymyxin B is particularly valuable for treating infections caused by extensively drug-resistant (XDR) or multidrug-resistant (MDR) bacteria – bacteria that have developed resistance to multiple other antibiotics [1]. The most common resistant bacteria treated with polymyxin B include:

  • Acinetobacter baumannii – A bacterium commonly found in hospital environments that can cause severe pneumonia and blood infections [4].
  • Pseudomonas aeruginosa – A common cause of healthcare-associated infections that is frequently resistant to multiple antibiotics [4].
  • Klebsiella pneumoniae – A bacterium that can cause various types of healthcare-associated infections, including pneumonia and bloodstream infections [14].
  • Carbapenem-resistant Enterobacterales (CRE) – A group of bacteria that have developed resistance to carbapenem antibiotics, which are themselves considered last-resort treatments [19].

Besides its use in systemic infections, polymyxin B is also found in various topical preparations used for:

  • Eye infections (in combination with other antibiotics) [8]
  • Skin infections and wounds [10]
  • Ear infections [18]

Treating Gram-Negative Bacterial Infections

Polymyxin B is specifically effective against Gram-negative bacteria. These bacteria have a distinctive outer membrane containing lipopolysaccharide (LPS) molecules, which polymyxin B targets. This makes the drug particularly useful for infections caused by Gram-negative bacteria that have become resistant to other antibiotics [1].

The increasing prevalence of resistant bacteria has made polymyxin B increasingly important in clinical practice. For example, in one study investigating the efficacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in Thailand, researchers found that polymyxin B could be an effective treatment option when other antibiotics fail [1].

Administration Methods

Polymyxin B can be administered in several different ways, depending on the type and location of the infection:

  • Intravenous (IV) administration: For serious systemic infections, polymyxin B is most commonly given intravenously. The drug is typically infused over 1-2 hours to minimize side effects [1]. In some protocols, it’s given twice daily, with each dose infused over 2 hours [4].
  • Intrathecal/intraventricular administration: For intracranial infections (infections in the brain), polymyxin B can be administered directly into the cerebrospinal fluid space. This method is used when the infection is in the brain and spinal cord, where it may be difficult for intravenous antibiotics to reach in sufficient concentrations [2].
  • Nebulized (inhaled) administration: For respiratory infections, especially ventilator-associated pneumonia, polymyxin B can be delivered via nebulization (as an inhalation therapy). This allows the drug to directly reach the lungs. Often, nebulized colistin (another polymyxin antibiotic) is used alongside intravenous polymyxin B [9].
  • Topical application: For localized infections of the skin, eyes, or ears, polymyxin B is available in various topical formulations, often combined with other antibiotics like neomycin or bacitracin [10].

The choice of administration method depends on the site and severity of infection, the patient’s condition, and other factors determined by healthcare providers [4].

Dosage

The dosage of polymyxin B varies based on several factors, including the type and severity of infection, the patient’s weight, kidney function, and whether it’s being used alone or in combination with other antibiotics. From clinical studies, some common dosing protocols include:

  • For intravenous administration in adults: 1.5-2.5 mg/kg/day divided into two doses (typically 0.75-1.25 mg/kg every 12 hours), infused over 1-2 hours [1].
  • For intravenous administration measured in units: 12,500-15,000 International Units (IU)/kg/day, typically divided into two doses [18]. (Note: polymyxin B is sometimes dosed in units rather than milligrams).
  • For nebulized administration: Doses range from 25 mg to 50 mg every 12 hours, typically diluted in 5 ml of saline solution [9].
  • For topical applications: Dosing varies widely depending on the specific product and application site [16].

The duration of treatment typically ranges from 7 to 14 days, depending on the site and severity of infection and the patient’s response to treatment [1].

It’s important to note that dosing may need to be adjusted for patients with kidney problems, as polymyxin B is primarily eliminated through the kidneys [5].

Effectiveness

Clinical studies have shown polymyxin B to be effective against many multidrug-resistant Gram-negative bacterial infections. Several outcomes measured in clinical trials provide insights into its effectiveness:

  • Mortality rates: One of the primary measures of effectiveness is the 28-day all-cause mortality rate after treatment with polymyxin B. Studies have examined whether polymyxin B reduces mortality compared to other treatments or when used in combination with other antibiotics [2].
  • Microbiological clearance: This measures whether the bacteria causing the infection are eliminated from the body. Studies assess microbiological clearance by performing cultures of blood, sputum, or other relevant samples to check if bacteria are still present after treatment [1].
  • Clinical cure: This refers to the resolution of signs and symptoms of infection, such as fever, abnormal white blood cell count, and other indicators of infection [3].
  • Time to defervescence: This measures how quickly a patient’s fever resolves after starting treatment [4].

Research indicates that polymyxin B is particularly effective against certain extensively drug-resistant bacteria, including Acinetobacter baumannii, Pseudomonas aeruginosa, and some carbapenem-resistant Enterobacterales [4]. However, its effectiveness may vary depending on the specific bacteria involved, the site of infection, and patient factors.

Side Effects and Safety

Like all medications, polymyxin B can cause side effects. It’s important for patients to be aware of these potential adverse effects while understanding that not everyone will experience them. The most significant side effects include:

  • Nephrotoxicity (kidney damage): This is one of the most serious and common side effects of polymyxin B. Studies monitor kidney function in patients receiving polymyxin B to assess the development of acute kidney injury [1]. The risk appears to be related to the dose and duration of treatment.
  • Neurotoxicity (nerve damage): Polymyxin B can affect the nervous system, leading to symptoms such as dizziness, confusion, tingling sensations, or even more severe manifestations like seizures or respiratory paralysis [1]. These effects are typically dose-related and may be more common with higher doses or in patients with kidney dysfunction.
  • Allergic reactions: Some patients may develop allergic reactions to polymyxin B, ranging from mild rashes to severe anaphylaxis (a life-threatening allergic reaction) [4].
  • Local reactions: When used topically, polymyxin B may cause local irritation, redness, or other skin reactions [10].

The safety profile of polymyxin B requires careful monitoring during treatment. Physicians typically assess kidney function regularly and may adjust the dose or discontinue the drug if significant kidney injury develops. Monitoring for signs of neurotoxicity is also important [5].

For patients with existing kidney problems, polymyxin B must be used with caution, and the dose may need to be adjusted. A pharmacokinetic study has been conducted to better understand how polymyxin B is processed in the body in patients with various degrees of kidney function, which may help guide safer dosing [5].

Special Considerations

There are several important considerations for specific patient populations or clinical scenarios when using polymyxin B:

  • Patients with kidney disease: Since polymyxin B can cause kidney damage and is eliminated through the kidneys, patients with pre-existing kidney problems require special attention. Dosage adjustments may be necessary, and more frequent monitoring of kidney function is typically recommended [5].
  • Critically ill patients: Polymyxin B is often used in critically ill patients in intensive care units. These patients may have altered drug metabolism and elimination, which can affect how polymyxin B works in their bodies. Additionally, they may be at higher risk for certain side effects due to their overall condition [3].
  • Patients on mechanical ventilation: For patients with ventilator-associated pneumonia, a combination of intravenous and nebulized polymyxins (polymyxin B or colistin) may be used to maximize drug delivery to the lungs [9].
  • Patients undergoing hematopoietic stem cell transplantation: Polymyxin B (often combined with vancomycin) has been used for gut decontamination in patients undergoing stem cell transplantation to prevent certain complications, though the benefits of this practice are being reassessed [3].

It’s also worth noting that the pharmacokinetics (how the drug moves through the body) of polymyxin B can vary significantly between individuals. Studies have measured blood levels of the drug at various time points after administration to better understand these variations and optimize dosing [1].

Combination Therapies

Polymyxin B is often used in combination with other antibiotics to improve effectiveness, particularly against highly resistant bacteria. Several combinations have been studied:

  • Polymyxin B + Carbapenems: The combination of polymyxin B with carbapenem antibiotics (such as meropenem) has been studied for treating multidrug-resistant Gram-negative infections. The MUSEUM trial examined whether this combination is more effective than polymyxin B alone [3].
  • Polymyxin B + Tigecycline/Eravacycline: For certain resistant infections, particularly those caused by Acinetobacter or Enterobacterales, combining polymyxin B with tigecycline or eravacycline may be effective [19].
  • Polymyxin B + Sulbactam: This combination has shown promise against carbapenem-resistant Acinetobacter infections [19].
  • Polymyxin B + Doripenem: A randomized controlled trial examined whether the combination of polymyxin B with doripenem is more effective than polymyxin B alone for extensively drug-resistant Gram-negative bacteria [4].
  • Polymyxin B + Fosfomycin: This combination has been studied for its effectiveness against certain resistant bacteria [14].
  • Polymyxin B + BV100: A newer investigational combination being studied for ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii [18].

The rationale for combination therapy includes potentially achieving synergistic effects (where the combined effect is greater than the sum of individual effects), preventing the emergence of resistance during treatment, and possibly allowing for lower doses of polymyxin B to reduce toxicity [4].

Laboratory methods like “checkerboard assays” and “time-kill assays” are used to evaluate the effectiveness of different antibiotic combinations against specific bacterial isolates [14].

Emerging Research

Research on polymyxin B continues to evolve, with several areas of active investigation:

  • Optimizing dosing regimens: Studies are examining the relationship between drug concentration in the blood and clinical outcomes to establish the most effective and safest dosing strategies [5].
  • Combination therapies: Ongoing research is exploring which antibiotic combinations work best for different types of resistant infections. The TREAT-GNB platform trial is evaluating multiple treatment options for severe Gram-negative bacterial infections [19].
  • Alternative administration routes: Studies are investigating the effectiveness of different administration methods, such as nebulized polymyxin B for respiratory infections or intraventricular administration for brain infections [2][9].
  • Impact of gut decontamination: Research is examining how polymyxin B affects the gut microbiome when used for selective digestive decontamination, a practice aimed at preventing certain infections in critically ill patients [3][13].
  • Novel uses: Beyond its traditional use as an antibiotic, polymyxin B is being studied for other potential applications, such as neutralizing bacterial endotoxins to reduce inflammation [5].

As antibiotic resistance continues to be a global health challenge, research on polymyxin B and other last-resort antibiotics remains crucial for developing effective treatment strategies for difficult-to-treat infections [19].

Aspect Details
Administration Methods – Intravenous: Standard dose 1.25-2.5 mg/kg/day divided into two doses
– Intracranial: Direct administration for brain infections
– Nebulized: For respiratory infections (25-50mg diluted in saline)
– Topical: For skin and eye conditions
– Combinations of multiple routes (IV+nebulized)
Target Infections – Ventilator-associated pneumonia (VAP)
– Hospital-acquired pneumonia (HAP)
– Bloodstream infections
– Intracranial infections
– Extensively drug-resistant (XDR) gram-negative infections
Target Pathogens – Carbapenem-resistant Acinetobacter baumannii (CRAB)
– Carbapenem-resistant Pseudomonas aeruginosa
– Carbapenem-resistant Enterobacterales
– Other multidrug-resistant gram-negative bacteria
Combination Therapies – Polymyxin B + carbapenems (meropenem, doripenem)
– Polymyxin B + tigecycline/eravacycline
– Polymyxin B + sulbactam
– Polymyxin B + ceftazidime-avibactam
– Polymyxin B + fosfomycin
Primary Outcome Measures – 28-day all-cause mortality
– Clinical cure rate
– Microbiological clearance
– Pharmacokinetic parameters (Cmax, AUC)
Secondary Outcome Measures – Adverse drug reactions (especially nephrotoxicity)
– Length of hospital/ICU stay
– Time to defervescence (fever resolution)
– Recurrence of infection
– Peak plasma concentration
Special Populations – Patients with renal insufficiency
– Critically ill trauma patients
– Patients undergoing mechanical ventilation
– Patients with high risk of multidrug-resistant infections
Safety Considerations – Nephrotoxicity monitoring
– Neurotoxicity assessment
– Kidney function testing
– Dose adjustment based on renal function
– Monitoring for secondary infections

FAQ

  • What is Polymyxin B sulfate used to treat? Polymyxin B sulfate is primarily used to treat serious infections caused by multidrug-resistant gram-negative bacteria. It's particularly effective against extensively drug-resistant (XDR) gram-negative bacteria including Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and other carbapenem-resistant Enterobacterales. Clinical trials are studying its use in treating various conditions including ventilator-associated pneumonia, hospital-acquired pneumonia, bloodstream infections, and intracranial infections when other antibiotics have failed.
  • How is Polymyxin B administered in clinical settings? Polymyxin B can be administered through multiple routes depending on the infection site. Most commonly, it's given intravenously (through a vein) for systemic infections at doses of 1.25-2.5 mg/kg/day divided into two doses. For certain conditions like intracranial infections, it may be administered directly into the brain (intracranially). Some studies are also investigating nebulized administration (inhaled as a mist) for respiratory infections, topical application for skin conditions, and combinations of different administration routes. For ventilator-associated pneumonia, some protocols use both intravenous and nebulized forms simultaneously.
  • What are the major side effects or risks associated with Polymyxin B treatment? The two most significant side effects of Polymyxin B are nephrotoxicity (kidney damage) and neurotoxicity (nervous system damage). Clinical trials carefully monitor kidney function through laboratory tests during treatment. Other potential adverse effects include diarrhea, allergic reactions, and superinfections (new infections that develop during antibiotic treatment). The risk of toxicity is often dose-dependent, which is why researchers are studying optimal dosing strategies across different patient populations, especially in those with existing kidney problems. Some trials are specifically designed to examine the pharmacokinetics (how the drug moves through the body) in patients with renal insufficiency.
  • Is Polymyxin B typically used alone or in combination with other antibiotics? Multiple clinical trials are comparing Polymyxin B monotherapy (used alone) versus combination therapy approaches. Current research suggests that combining Polymyxin B with other antibiotics may be more effective for treating resistant infections than using it alone. Common combination partners include carbapenems (like meropenem or doripenem), ceftazidime-avibactam, tigecycline, and fosfomycin. These combinations aim to achieve synergistic effects, where the drugs work together more effectively than either would alone. For example, the MUSEUM trial specifically examines Polymyxin B monotherapy versus Polymyxin B-carbapenem combination therapy in critically ill patients with multidrug-resistant gram-negative infections.
  • How effective is Polymyxin B against resistant bacterial infections? Polymyxin B has shown effectiveness against many multidrug-resistant gram-negative bacterial infections, particularly when other antibiotics have failed. Its mechanisms of action include disrupting bacterial cell membranes, acting as a surfactant to penetrate cell membranes, and neutralizing bacterial endotoxins. However, researchers are concerned about emerging resistance to polymyxins and treatment failures, which is why many clinical trials are focusing on combination approaches. Studies are measuring effectiveness through outcomes like 28-day mortality rates, clinical cure rates, microbiological clearance (elimination of bacteria from cultures), and time to improvement of symptoms. The ultimate effectiveness depends on factors like the specific bacteria involved, the site of infection, patient characteristics, and whether it's used alone or in combination.

Ongoing Clinical Trials on POLYMYXIN B SULFATE

  • Study Comparing Oral Fluoroquinolones or Trimethoprim-Sulfamethoxazole to IV Therapy in Stable Patients with Gram-Negative Blood Infections

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Greece Italy Spain

Glossary

  • Carbapenem-resistant: Bacteria that have developed resistance to carbapenem antibiotics, which are considered last-resort antibiotics for many serious infections. This resistance makes infections much harder to treat.
  • Clinical cure: The resolution of all signs and symptoms of infection as determined by clinical examination. Often measured at specific timepoints (like 14, 28, or 90 days) after starting treatment.
  • Extensively drug-resistant (XDR): Bacteria that are resistant to almost all available antibiotics, including carbapenems, beta-lactams, aminoglycosides, fluoroquinolones, and other common antibiotics, with the exception of a few options like polymyxins.
  • Gram-negative bacteria: A class of bacteria that do not retain crystal violet dye in the Gram staining protocol. They have a thin peptidoglycan layer and an outer membrane containing lipopolysaccharides (LPS). Common examples include E. coli, Klebsiella, Pseudomonas, and Acinetobacter.
  • Hospital-acquired pneumonia (HAP): A lung infection that develops 48 hours or longer after admission to a hospital in patients who didn't have pneumonia when they were admitted.
  • Intracranial administration: Delivery of medication directly into the brain or cerebrospinal fluid, often used for treating infections that have penetrated the central nervous system.
  • Microbiological clearance: The elimination of disease-causing bacteria from the body, typically confirmed through negative culture results from samples like blood, sputum, or other tissues.
  • Monotherapy: Treatment using a single medication, as opposed to combination therapy which uses multiple medications simultaneously.
  • Nebulized administration: Delivery of medication as a fine mist that can be inhaled directly into the lungs, often used for respiratory infections.
  • Nephrotoxicity: Damage to the kidneys caused by medication or other substances. This is one of the major side effects of Polymyxin B that requires monitoring.
  • Neurotoxicity: Damage to the nervous system caused by exposure to natural or artificial toxic substances. A significant potential side effect of Polymyxin B treatment.
  • Pharmacokinetics (PK): The study of how drugs move through the body, including absorption, distribution, metabolism, and excretion. PK studies help determine optimal dosing strategies.
  • Selective Digestive Decontamination (SDD): A preventive strategy that uses antibiotics to reduce the number of potentially harmful bacteria in the digestive tract to prevent infections in critically ill patients.
  • Synergistic effect: When two drugs work together to produce an effect greater than the sum of their separate effects. Many combination therapies with Polymyxin B aim to achieve synergistic effects against resistant bacteria.
  • Ventilator-associated pneumonia (VAP): A type of lung infection that develops in people who are on mechanical ventilation breathing machines in hospitals, typically 48 hours or more after intubation.

References

  1. https://clinicaltrials.gov/study/NCT02328183
  2. https://clinicaltrials.gov/study/NCT06595979
  3. https://clinicaltrials.gov/study/NCT03159078
  4. https://clinicaltrials.gov/study/NCT02134106
  5. https://clinicaltrials.gov/study/NCT05359627
  6. https://clinicaltrials.gov/study/NCT00000635
  7. https://clinicaltrials.gov/study/NCT00534391
  8. https://clinicaltrials.gov/study/NCT06076603
  9. https://clinicaltrials.gov/study/NCT01429701
  10. https://clinicaltrials.gov/study/NCT05685615
  11. https://clinicaltrials.gov/study/NCT02641236
  12. https://clinicaltrials.gov/study/NCT03950544
  13. https://clinicaltrials.gov/study/NCT04839653
  14. https://clinicaltrials.gov/study/NCT00997139
  15. https://clinicaltrials.gov/study/NCT05063422
  16. https://clinicaltrials.gov/study/NCT02186457
  17. https://clinicaltrials.gov/study/NCT03920007
  18. https://clinicaltrials.gov/study/NCT02344732
  19. https://clinicaltrials.gov/study/NCT07004049